Absci is a drug and target discovery company. Co. develops an integrated drug creation platform by merging deep learning artificial intelligence (AI) and synthetic biology. The integrated drug creation platform enables target identification, and parallel discovery of biologics and with production cell lines by incorporating biodiversity, high-throughput single cell single cell assays, and deep learning AI models. Co. uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and Co. learns from the data it generates. Co.'s designs are AI-informed and its technology platform is scaffold-agnostic. The ABSI YTD return is shown above.
The YTD Return on the ABSI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ABSI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABSI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|